Research and Development (RD)

Revive Therapeutics, UCSF partner to study Bucillamine for severe Covid-19

Specialty life sciences company Revive Therapeutics has signed a research agreement with University of California, San Francisco (UCSF) to study Bucillamine as a potential treatment for severe Covid-19.

Dyadic and Medytox to co-develop Covid-19 variant fighting vaccines

US-based global biotechnology company Dyadic International has announced the expansion of its partnership with South Korea-based global research biopharmaceutical company Medytox to co-develop C1 manufactured Covid-19 vaccines.

USFDA grants priority review to Merck’s NDA for HIF-2α inhibitor Belzutifan

The US Food and Drug Administration (FDA) has granted priority review for Merck’s New Drug Application (NDA) for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan.

NIAID grants $2.5m to 12 institutes for bacteriophage therapy research

A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.

NIH study finds severe Covid-19 during pregnancy leads to complications

Preliminary findings from a study funded by the National Institutes of Health (NIH) has found that pregnant women with severe Covid-19 symptoms had a higher risk of complications during and after pregnancy.

GE researchers begin in-depth study to understand Covid-19 impact on lungs

Bioscience researchers at GE Research have begun an in-depth study to better understand the impact of the Covid-19 virus on the lungs.

Existing drug offers targeted treatment for aggressive breast cancer

A new study claims palbociclib, an approved breast cancer drug, can treat an aggressive form of the cancer, bringing hope to thousands of afflicted women in the UK.

Merck discontinues Covid-19 vaccine candidates on grounds of poor performance

American pharma giant Merck has announced that it has discontinued the development of its SARS-CoV-2/Covid-19 vaccine candidates V590 and V591, after they performed poorly in phase 1 clinical trials.

Novartis, GSK team up for $3.6m genetic diversity research in Africa

Swiss pharma giant Novartis and British pharmaceuticals company GSK have teamed up to conduct scientific research linking genetic diversity in Africa and its potential impact on response to drug therapeutics.